By targeting receptors such as CD16a, NKp46, NKp30, NKG2C, and NKG2D, NKCEs provide innovative solutions to counter tumor immune evasion, offering improved therapeutic efficacy across a wide range of cancer types. This evidence concerns the gene FCGR3A and cancer.